Amerikanische Gesellschaft für Hirudotherapie

Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review

Narrative review published in Anesth Analg (2019)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungKlinische StudienZaleski KL et al. · Anesthesia and analgesia, 2019

Abstract

Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin inhibitor, has found increasing utilization as a heparin alternative in the pediatric population, most commonly for the treatment of thrombosis secondary to heparin-induced thrombocytopenia. Due to the relative rarity of heparin-induced thrombocytopenia as well as the lack of Food and Drug Administration-approved indications in this age group, much of what is known regarding the pharmacokinetics and pharmacodynamics of bivalirudin in this population has been extrapolated from adult data. This narrative review will present recommendations regarding the use of bivalirudin for procedural anticoagulation in the pediatric population based on the published literature.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAdolescentAge FactorsAntithrombinsBlood CoagulationCardiac CatheterizationCardiac Surgical ProceduresCardiopulmonary BypassChildChild, PreschoolDrug Administration ScheduleDrug Dosage CalculationsHemorrhage

Zusammenfassung

Narrative review consolidating pediatric procedural bivalirudin recommendations, primarily for treatment of HIT thrombosis, with pediatric pharmacokinetics/pharmacodynamics extrapolated from adult data.

Warum dies für die Hirudotherapie relevant ist

This narrative review synthesizes the published literature on bivalirudin—a direct thrombin inhibitor—for procedural anticoagulation in the pediatric population, most commonly for thrombosis secondary to heparin-induced thrombocytopenia. The authors note that much of the pediatric pharmacokinetic and pharmacodynamic understanding is extrapolated from adult data, owing to the rarity of HIT in children and the absence of FDA-approved indications in this age group. The abstract does not mention hirudin, leeches, or any leech-derived compound, so no defensible hirudotherapy link can be drawn from this article. This is a review article without original data, does not involve leeches or hirudotherapy, and provides practice recommendations rather than new clinical findings.

Zitation

Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.

Zaleski KL et al. · Anesthesia and analgesia, 2019

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsClinical EvidenceClinical ApplicationsBivalirudinAnticoagulation CompoundsHemostasisPediatricsOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.